New drug duo aims to shrink tough cancers

NCT ID NCT06475300

Recruiting now Disease control Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 24, 2026 · Updated 2 times

Summary

This study tests a new drug called BL-B01D1 combined with an immunotherapy (PD-1 antibody) in people with advanced lung cancer, nasopharyngeal cancer, or other solid tumors that have spread. The goal is to see if the combination can shrink tumors and control the disease. About 570 adults will take part, and the trial is currently recruiting.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: BL-B01D1 (a drug) combined with a PD-1 monoclonal antibody (an immunotherapy)
What this could lead to: If successful, this combination could offer a new treatment option for people with advanced lung cancer, nasopharyngeal cancer, or other solid tumors.
What could go wrong: This is an early-phase trial (Phase 2) with no results yet. The combination may not work better than existing treatments, and side effects from the drugs could be serious.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NASOPHARYNGEAL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

nasopharyngeal carcinoma non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NASOPHARYNGEAL CARCINOMA NON-SMALL CELL LUNG CANCER SOLID TUMOR

Contacts and locations

Locations

Sun Yat-sen University Cancer Center
RECRUITING

Guangzhou, Guangdong, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.